Once-weekly epoetin alfa improves quality of life and increases hemoglobin in anemic HIV+ patients

AIDS Research and Human Retroviruses

Volumn 20, Issue 10, 2004, Pages 1037-1045

  Saag, Michael S ^a,e   Bowers, Peter ^b   Leitz, Gerhard J ^c   Levine, Alexandra M ^d  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^c Ortho Biotech Products LP   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ADEFOVIR; AMPRENAVIR; ANABOLIC AGENT; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; HYDROXYUREA; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RECOMBINANT ERYTHROPOIETIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DOSE CALCULATION; DRUG TOLERABILITY; DYSPNEA; ENERGY; FATIGUE; FEMALE; FEVER; HEALTH STATUS; HEMOGLOBIN DETERMINATION; HEMOLYTIC ANEMIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; KAPOSI SARCOMA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MULTICENTER STUDY; MYCOSIS; NAUSEA; OPEN STUDY; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; THROMBOCYTOPENIA; VIRUS LOAD; VOMITING;

ADULT; AGED; ANEMIA; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COMBINED MODALITY THERAPY; EPOETIN ALFA; FEMALE; HEMATINICS; HEMOGLOBINS; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 6344241814     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2004.20.1037     Document Type: Article

References (32)

1. Semba RD, Shah N, Strathdee SA, and Vlahov D: High prevalence of iron deficiency and anemia among female injection drug users with and without HIV infection. J Acquir Immune Defic Syndr 2002;29:142-144.
2. Semba RD, Shah N, Klein RS, Mayer KH, Schuman P, and Vlahov D: HER Human Immunodeficiency Virus Epidemiology Research Study Group. Prevalence and cumulative incidence of and risk factors for anemia in a multicenter cohort study of human immunodeficiency virus-infected and -uninfected women. Clin Infect Dis 2002;34:260-266.
3. Lundgren JD, Mocroft A, Gatell JM, et al.: The change in risk of clinical progression after initiation of HAART: The EuroSIDA study. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, 340, 2000 (abstract).
4. Creagh T, Mildvan D, Bohn H, Moore R, and Ray L: A case-control study to examine the association of anemia with HIV/AIDS progression: Results from the 1996 enrollment cohort. The 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina, July 9, 2001 (abstract ANO. 318).
5. Levine AM, Berhane K, Masri-Lavine L, et al.: Prevalence and correlates of anemia in a large cohort of HIV-infected women: Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2001;26:28-35.
6. Servais J, Nkoghe D, Schmit J-C, et al.: HIV-associated hematologic disorders are correlated with plasma viral load and improve under highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001;28:221-225.
7. Palella FJ Jr, Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-860.
8. Grossman HA, Goon B, Bowers P, Leitz G, and the 010 Study Group: Once-weekly epoetin alfa dosing is as effective as three-times-weekly dosing in increasing hemoglobin levels and is associated with improved quality of life in anemic, HIV-infected patients. J Acquir Immune Defic Syndr 2003;34:368-378.
9. Abrams DI, Steinhart C, and Frascino R: Epoetin alfa therapy for anaemia in HIV-infected patients: Impact on quality of life. Int J STD AIDS 2000;11:659-665.
10. Henry DH, Beall GN, Benson CA, et al.: Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Ann Intern Med 1992;117:739-748.
11. Revicki DA, Brown RE, Henry DH, McNeill MV, Rios A, and Watson T: Recombinant human erythropoietin and health-related quality of life in AIDS patients with anemia. J Acquir Immune Defic Syndr 1994;7:474-484.
12. Moore RD Keruly JC, and Chaisson RE: Anemia and survival in HIV infection. J Acquir Immune Defic Syndr 1998;19:29-33.
13. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, and Vadhan-Raj S: Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 1997;15:1218-1234.
14. Demetri GD, Kris M, Wade J, Degas L, and Cella D: Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. J Clin Oncol 1998;16:3412-3425.
15. Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, and Einhorn LH: Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;9:2875-2882.
16. McCormack HM, Horne DJ, and Sheather S: Clinical applications of visual analog scales: A critical review. Psychol Med 1988;18:1007-1009.
17. Revicki DA, Sorensen S, and Wu AW: Reliability and validity of physical and mental health summary scores from the Medical Outcomes Study HIV Health Survey. Med Care 1998;3:126-137.
18. Delate T and Coons SJ: The use of 2 health-related quality-of-life measures in a sample of persons infected with human immunodeficiency virus. Clin Infect Dis 2001;32:e47-e52.
19. Wachtel T, Piette J Mor V, Stein M, Fleishman J, and Carpenter C: Quality of life in persons with human immunodeficiency virus infection: Measurement by the Medical Outcomes Study Instrument. Ann Intern Med 1992;116:129-137.
20. Wu AW, Revicki DA, Jacobson D, and Malitz FE: Evidence of reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV). Qual Life Res 1997;6:481-493.
21. Crawford J, Demetri GD, Gabrilove JL, Blasi MV, Sarokhan BJ, and Glaspy J: Clinical benefits of epoetin alfa therapy in patients with lung cancer. Clin Lung Cancer 2002;3:180-190.
22. Littlewood TJ, Bajetta E, Nortier JWR, Vercammen E, Rapoport B, and the Epoetin Alfa Study Group: Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind placebo-controlled trial. J Clin Oncol 2001;19:2865-2874.
23. Volberding P, for the Anemia in HIV Working Group: Consensus statement: Anemia in HIV infection-current trends, treatment options, and practice strategies. Clin Ther 2000;22:1004-1020.
24. Fischl M, Galpin JE, Levine JD, et al.: Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N Engl J Med 1990;322:1488-1493.
25. Moore RD: Improved survival with correction of anemia in HIV disease. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, January 31, 1999 (abstract 706).
26. Sharp V, Paredes J, and Steinbock C: Anemia in HIV disease in the HAART era: Is it common? Blood 1999;94(Suppl. 1):8b (abstract 3179).
27. Mildvan D and Creagh T, for the Anemia Prevalence Study Group: Anemia more prevalent in women and African Americans with HIV/AIDS. The 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina, July 9, 2001 (abstract ANO. 319).
28. Mocroft A, Kirk O, Barton SE, et al.: Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. Acquir Immune Defic Syndr 1999;13:943-950.
29. Semba RD, Shah N, Klein RS, et al.: Highly active antiretroviral therapy associated with improved anemia among HIV-infected women. AIDS Patient Care STDs 2001;15:473-480.
30. Semba RD, Shah N, and Vlahov D: Improvement of anemia among HIV-infected drug users receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001;26:315-319.
31. Moore RD and Forney D: Anemia in HIV-infected patients receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002;29:54-57.
32. Sullivan PS, Hanson DL, Chu SY, Jones JL, and Ward JW: Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: Results from the Multistate Adult and Adolescent Spectrum of HIV Disease Surveillance Project. Blood 1998;91:301-308.